Organon & Co. Hits New 52-Week High at $13.38, Marking Key Milestone

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.38 on April 30, 2026. This achievement marks a notable recovery from its 52-week low of USD 5.69, showcasing a substantial upward movement in the stock's performance. Despite the recent high, Organon & Co. has experienced a challenging year, with a one-year performance decline of 36.02%, contrasting sharply with the S&P 500's gain of 29.45%. The company's market capitalization stands at USD 1,650 million, reflecting its position within the small-cap segment of the market. Financial metrics reveal a price-to-earnings (P/E) ratio of 3.00, indicating a potentially undervalued stock relative to earnings. Additionally, the company offers a dividend yield of 0.94%, although its return on equity remains at 0.00%. With a debt-to-equity ratio of 8,066.00, these figures provide insight into Organon & Co.'s financial health and market standing within the competitive landscape of the pharmaceuticals industry.